We showed that breakpoints on BCL2 involved in t(14;18)(q32;q21) translocation are not only clustered within two common sites, i.e., major breakpoint cluster region (MBR) and minor cluster region (mcr), but also distributed over a large region from the MBR through mcr.
Rearrangement of the BCL2 gene with the immunoglobulin (IG) heavy chain gene (IGH) is one of the most frequent genetic abnormalities in B-cell tumors. 1, 2) We showed that breakpoints on BCL2 involved in t(14;18)(q32;q21) translocation are not only clustered within two common sites, i.e., major breakpoint cluster region (MBR) and minor cluster region (mcr), but also distributed over a large region from the MBR through mcr.
3) As a result of t (14;18) , the coding exons of BCL2 are juxtaposed 5′ to a joining (J) segment of IGH (JH) in the same transcriptional orientation. Therefore, an erroneous variable (V)/diversity (D)/J recombination process at the stage of B-cell precursor is likely responsible for the formation of this translocation, although this issue is still controversial. [4] [5] [6] The 5′ flanking region of BCL2 (5′-BCL2) is another breakpoint cluster of the translocation between BCL2 and IGs. In contrast to t(14;18), 5′-BCL2/IGs translocation can involve not only IGH, but also two light chain gene (IGL) loci as partners, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and fusion between the relevant genes occurs in divergent orientation. However, the precise anatomy of the 5′-BCL2/IGs fusion gene, as well as its influence on the expression of BCL2 in large numbers of cases, has not been described. Another particular feature of 5′-BCL2/IGs translocations is that they are observed in various types of B-cell tumors, including chronic lymphocytic leukemia (CLL), 13, 16) follicular lymphoma (FL) 8, 11, 12) and diffuse large cell lymphoma (DLCL). 7, 8) Thus, it is possible that the role of 5′-BCL2/IGs translocation in the pathogenesis of B-cell tumors may not be identical to that of t(14;18), which is closely associated with FL.
We have developed a long-distance (LD-) PCR method, which is capable of amplifying oncogene/IG junctions of up to 30 kb in size. 3, 17) Here, we cloned and sequenced a total of eleven 5′-BCL2/IGs fusion genes of B-cell tumors using an LD-PCR-based approach. We next studied levels of transcription of the BCL2 gene in 5′-BCL2/IG-carrying cells and compared them with those in t(14;18) cells.
MATERIALS AND METHODS

Patients and established cell lines The patient popula-
The first three authors contributed equally to this work. 2 To whom correspondence should be addressed. E-mail: hohno@kuhp.kyoto-u.ac.jp tion consisted of 9 patients with various types of B-cell tumor, which were confirmed to have rearrangements of 5′-BCL2 by Southern blot hybridization. Of the 9 patients, one had CLL (no. 491), one had FL (no. 61), five had DLCL and the immunoblastic variant (nos. 472, 517, 585, 1001 and 1077), and the remaining two lacked lymphadenopathy but presented with leukemic manifestations (nos. 605 and 1122). More clinical details of 7 of those patients were described previously.
8) The Boar88 cell line was established from leukemic cells of a patient with FL. YM 7) and ShK cell lines were derived from clinical materials of nos. 1001 and 1077, respectively. KIS-1, FL-18, FL-218, FL-318 and FL-418 cell lines were described elsewhere. 18) These cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum under the standard culture conditions. Southern and northern blot hybridization Genomic DNA was digested with restriction enzymes, electrophoresed through 0.8% agarose gels, and transferred onto nylon membrane filters (GeneScreen Plus, NEN Research Products, Boston, MA). Total cellular RNA was prepared using an RNeasy Total RNA Kit (Qiagen, Hilden, Germany), electrophoresed on 1.0% agarose gels containing 0.66 M formaldehyde and transferred onto membranes. The membranes were hybridized with probes labeled with 32 P-dCTP (Amersham Pharmacia Biotech, Buckinghamshire, England) using a random primer labeling system (Amersham Pharmacia Biotech). Hybridization and washing conditions were as recommended by the manufacturer. pB16 probe was a cDNA fragment corresponding to the second exon of BCL2 and was used to detect rearrangements within 5′-BCL2.
15) The MBR probe was 'probe b' 19) provided by Dr. Y. Tsujimoto. LD-and LD-inverse (LDI-) PCR Oligonucleotide primers and PCR cycling conditions for LD-PCR to detect 5′-BCL2/IGs fusion genes were described in our previous papers. 7, 17) Cλ/04 primer was newly designed for efficient amplification; the sequence was 5′-CTGTCTTCTCCAC-GGTGCTCCCTTCATGCGTGACCY-3′. LDI-PCR was developed to amplify unknown sequences adjacent to a known DNA segment. 20, 21) Briefly, genomic DNA was digested with appropriate restriction enzymes and purified by standard methods. The DNA was diluted to a concentration of 1 µg/ml and incubated at 16°C overnight in the presence of T4 DNA ligase to facilitate intramolecular ligation. The self-ligated circular DNA was used as a template for nested PCR. The primers designed for the known 5′-BCL2 sequences were: YAB/01, 5′-CCACCCCACG-GCCCCCAGAGAAAGAAGAGGAGTTA-3′; YAB/02, 5′-AATCCAAGGTGGTAACTGGTATCTGTCTATCAA-AT-3′; and YAB/03, 5′-GCATACAGACAGATTTTCTT-CACATTTACTACCAA-3′. Molecular cloning and nucleotide sequencing The PCR products were cloned into the plasmid pCR2.1 (Invitrogen, San Diego, CA) and DNA was extracted using a QIAprep Spin Miniprep Kit (Qiagen). Nucleotide sequencing was performed with a BigDye Terminator Cycle Sequencing Kit (PE Applied Biosystems, Foster City, CA), and the sequencing reactions were resolved on an ABI 310 automated sequencer (PE Applied Biosystems). The GenBank sequence database at the National Center of Biotechnology Information was accessed on the World Wide Web. The Basic Local Alignment Search Tool (BLAST) was used to identify nucleotide homology.
RESULTS
Amplification of 5′ ′ ′ ′-BCL2/IGs fusion genes by LD-PCR-based assays
We and others have cloned and characterized fusion genes consisting of 5′-BCL2 and three IGs loci; i.e. 5′-BCL2/IGH, 5′-BCL2/IGLκ and 5′-BCL2/IGLλ fusions. [7] [8] [9] [10] [11] [13] [14] [15] [16] To encompass the previously recognized breakpoints of these three types of fusion, we designed oligonucleotide primers for the second exon of BCL2, the Eµ enhancer of IGH, the Cκ constant gene of IGLκ and the consensus sequence of the Cλ constant genes of IGLλ. Since the 5′-BCL2/IGs fusions reported previously occurred in divergent orientation, these primers corresponded to the anti-sense strand in the reverse direction. 17) Genomic DNA from clinical materials of 9 patients and Boar88 was subjected to LD-PCR, and 7 were positive for amplification. Two cases had a 5′-BCL2/IGH fusion, three had a 5′-BCL2/IGLκ fusion and three had a 5′-BCL2/ IGLλ fusion gene; one case (no. 472) had two independent fusion genes. The amplified fragments ranged in size from 4.8 to 17.3 kb and were readily identifiable on ethidium bromide-stained gels (Fig. 1A) .
We next applied the LDI-PCR strategy for cases in which LD-PCR was negative (nos. 61 and 1122, and Boar88). Genomic DNA was digested with HindIII and the circularized DNA was subjected to LDI-PCR. The positions and orientations of nested primers are presented in Fig. 2 . As shown in Fig. 1B , the three cases had a unique LDI-PCR product, which was the expected size from the results of Southern blot analysis using the pB16 probe and the distance of the primers used. Distribution of breakpoints on 5′ ′ ′ ′-BCL2 The LD-and LDI-PCR products were cloned into plasmids for sequencing analysis. Using a set of primers designed for 5′-BCL2 in reverse orientation, we determined the positions of breakpoint on the 5′-BCL2. As illustrated in Fig. 2 , the breakpoints were distributed from 378 to 2312 bp upstream of the translational initiation site, confirming that the coding region of BCL2 was not disrupted by this type of translocation. Five breakpoints were close to or within the alternating purine-pyrimidine stretch reported previously. 22) Two were associated with the upstream P1 promoter, which is rich in G and C and contains multiple SP1 sites. 23) The other four breakpoints had no apparent association with characteristic sequences that were previously recognized within this area.
Heterogeneous breakpoints on IGs
We next determined the sequences of each IG partner (Fig. 3) . Two 5′-BCL2/ IGH and two 5′-BCL2/IGLκ fusions involved the 5′ region of J segments, and variable numbers of nucleotides of unknown origin were inserted at the breakpoints, most likely reflecting errors in V/(D)/J recombination. As compared with the germ line sequences of the Jκ3 and Jκ4 segments, there was considerable nucleotide diversity. In contrast, the breakpoint of one 5′-BCL2/IGLκ was localized downstream of the 3′ boundary of the Jκ segments, and two 5′-BCL2/IGLλ fusions occurred at points between the Vλ2-1, which is the most 3′ V gene of IGLλ, and the Jλ1 segment. There was no addition or deletion of nucleotides at these three 5′-BCL2/IGL fusions that occurred within the intronic sequences of IGs.
Three breakpoints recognized by LDI-PCR were not localized within the regions enclosed by primer sets for LD-PCR. The 5′-BCL2 sequences of no. 61 were contiguous to a series of regular pentamer repeats with the consensus CCCAG or CTCAG, which are complementary to the repeated motifs of IGH switch regions. 24) The sequences juxtaposed to the 5′-BCL2 in the Boar88 cell line matched those of the switch region associated with the Cγ1 constant gene. On the other hand, the IG partner of no. 1122 was the κ-deleting element (κ-de), 25, 26) which is localized 24 kb downstream of Cκ, and the joining point was immediately 3′ of the palindromic heptamer sequence. These three fusions occurred in the head-to-tail orientation. Fig. 4A shows comparative structures between the 17.3 kb LD-PCR product from no. 491, 5′-BCL2 and corresponding germ line IGLλ locus. The LD-PCR product included a 14.2 kb fragment that encompassed the Vλ1-16 and Vλ3-2 variable genes, localized ~0.5 megabases upstream of the Jλ1 segment. 27) Fusion with the 5′-BCL2 occurred immediately 3′ of the Vλ1-16, while the downstream Vλ3-2 joined to a Jλ segment. The Vλ3-2 gene of no. 491 carried multiple mutations in addition to a nucleotide insertion, resulting in a frame shift and therefore a non-producing configuration (Fig. 4B) . Expression of BCL2 in lymphoma cells associated with 5′ ′ ′ ′-BCL2/IGs fusion genes We established three cell lines that carried 5′-BCL2/IGs fusion genes. Cytogenetic analysis of ShK (5′-BCL2/IGLλ) and Boar88 (5′-BCL2/IGH) revealed that both cell lines had complex karyotypes including abnormalities of chromosomes 18 and 22 in ShK, and 14 and 18 in Boar88. The karyotype of YM (5′-BCL2/IGLκ) was described elsewhere. To study whether these genetic lesions altered the expression of BCL2 that was juxtaposed to each IG partner, we performed northern blot analysis using an MBR probe. Total cellular RNA isolated from leukemic cells of no. 605 was also subjected to this analysis. As indicated in Fig. 5 , YM, ShK and Boar88 cells as well as no. 605 showed markedly higher levels of BCL2 transcripts than those of t(14;18)-carrying cell lines; the latter cell lines carried BCL2/IGH fusion genes with breakpoints at the MBR or 3′-MBR.
3) As compared with the size of transcripts of a cell line with the germ line configuration of BCL2, 5′-BCL2/IGs-carrying cells expressed aberrantlysized BCL2 mRNA, indicating that these transcripts represent transcription from the rearranged allele.
DISCUSSION
In the present study, we cloned and sequenced a total of eleven 5′-BCL2/IGs fusion genes, and showed that heterogeneous breakpoints on IGs were involved in this type of oncogene/IG recombination. These included 5′ of J segments, 3′ of a V gene, κ-de, switch regions, and intronic sequences. Thus, it is apparent that errors in the V/(D)/J recombination process alone cannot account for the generation of 5′-BCL2/IGs fusion genes.
Recombination of IGL segments during B-cell differentiation occurs in an ordered fashion, such that recombination of IGLκ initiates prior to that of IGLλ. In λ-producing B-cells, a part of IGLκ is frequently deleted.
25) The κ-de, which is downstream of the Cκ, joins to a point within the Jκ-Cκ intron, resulting in deletion of the enhancer and Cκ elements. Since the κ-de is flanked by heptamer and nonamer signal sequences and a heptamer motif lies within the Jκ-Cκ intron, it is likely that this process of deletion of intervening sequences is mediated by the V/J recombination machinery.
26) The breakpoint of no. 1122 was localized immediately 3′ of the heptamer signal sequence; therefore, the 5′-BCL2/IGLκ fusion of this particular case was likely mediated by this deletional recombination. Indeed, the lymphoma cells of this case expressed λ light chain on their cell surface.
There are three types of molecular processes that modify the gene encoding antibody molecules; i.e. receptor editing, class switching and somatic hypermutation. 28) Receptor editing is a process by which the originally expressed antibody polypeptide chain is replaced by another. 28, 29) In the IGL loci, receptor editing is mediated by secondary rearrangements of the variable region gene, usually involving upstream V segments, and downstream J segments. In this process, the gene encoding the originally expressed light chain is deleted from the chromosome. Once this process leads to the expression of an 'innocent' immunoglobulin molecule, the B-cell leaves the bone marrow to become a naive B-cell.
28) The structure of 5′-BCL2/ IGLλ of no. 491 seems to match a theoretical intermediate of the receptor editing of IGLλ loci; the Vλ3-2/Jλ recombination occurred first and then secondary V/J recombination occurred erroneously between Vλ1-16 and 5′-BCL2. However, multiple mutations as well as a nucleotide insertion 30) leading to the out-of-frame rearrangement were introduced into the downstream Vλ3-2, suggesting that the cell was at the stage of germinal center (GC) or post-GC B-cell, when the 5′-BCL2/IGLκ recombination developed. These observations together with the presence of two 5′-BCL2/IGH cases involving switch regions suggest that a proportion of 5′-BCL2/IGs recombination events do not occur in the bone marrow, but in the peripheral lymphoid organs. The reactivation of recombination activation genes RAG1 and RAG2 in GC 31) may in part support the hypothesis that oncogene/IG translocation mediated by V/(D)/J recombination is not restricted to B-cell precursors in the bone marrow. 5, 28) The mechanisms responsible for the intronic breakpoints remain to be determined. We recently reported two DLCL cases with c-MYC/IGH translocation having JH-Eµ and four with BCL6/IGLλ having Vλ-Jλ1 and Jλ-Cλ 3) intronic breakpoints. 20, 32) There is evidence that c-MYC/ IGH and BCL6/IGs translocations are related to somatic hypermutation, which targets not only V genes of IGs, but also particular hot spots of these two oncogenes. 4, 6) Thus, it is possible that somatic mutations are also introduced within the introns in addition to the relevant oncogenes, thereby playing a role in the development of translocations. Indeed, small deletions and nucleotide substitutions were observed in 5′-BCL2. 33, 34) In summary, the results of the present study suggested that multiple molecular mechanisms are involved in the generation of 5′-BCL2/IGs translocations and that B-cells at heterogeneous stages of differentiation are targeted by this particular type of translocation, potentially accounting for the diverse clinicopathological features of B-cell tumors carrying rearrangement of 5′-BCL2.
The BCL2 gene is composed of three exons, and two potential promoter regions have been identified.
23) The P1 promoter is associated with exon 1, and is rich in G and C with multiple SP1 sites. In contrast, P2 is located 5′ to the open reading frame in exon 2, and has classic TATA and CAAT boxes. In lymphoma cells carrying t(14;18), breakpoints of the translocation are ~370 kb downstream of this promoter area, and the coding region of BCL2 separated by the extremely large intron is placed 5′ to a J segment of IGH. As the result of translocation, multiple chimeric transcripts that contain both the BCL2 and JH-CH messages are generated. 23) Thus, one possible mechanism for the deregulated expression of Bcl-2 protein is that replacement of the A and U-rich 3′ untranslated region of BCL2 mRNA with IGH components can alter the stability of BCL2 mRNA, 35) although an earlier study demonstrated comparable half-lives of BCL2 and BCL2/IGH fusion mRNA. 23) In the present study, we examined the level of BCL2 expression, the promoter of which is placed in close proximity to IGs. The results showed invariably high levels of BCL2 mRNA in 5′-BCL2/IGs-carrying cells irrespective of the diversity of the IG partners and juxtaposed segments. Thus, it was suggested that transcriptional activation of the BCL2 gene under the control of IG enhancer/ promoter activity is a particular feature of 5′-BCL2/IGs rearrangements. Our study suggested that the mechanisms underlying the formation of 5′-BCL2/IGs translocations and their pathogenetic role in B-cell tumors are not identical to those of t(14;18).
